Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06624787Not ApplicableNot Yet Recruiting

Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Role: collaborator

NCT04427280Completed

Cancer: Rapid Diagnostics and Immune Assessment for SARS-CoV-2 (COVID-19)

Role: collaborator

NCT04070196Not ApplicableCompleted

Point-of-care Test for Diagnosis of Peritonitis in Peritoneal Dialysis Patients

Role: collaborator

NCT04296318Terminated

COPD Exacerbation Alert System With urinE anaLysis Using the HEADSTART Device

Role: lead

NCT04297709Completed

Study of Urinary Predictors of Exacerbations by Biomarkers in Cystic Fibrosis

Role: lead

NCT03217552Unknown

The Performance of the Mologic Biomarker Panel in Infection

Role: lead

All 6 trials loaded